**Description**

**A FORMULATION INTENDED FOR TREATMENT OF AIDS**

**Field of Invention**

The present invention herewith is related to a formulation developed for treatment of AIDS

**Background of the Related Technology**

At present it is known that AIDS is a contagious disease that leads to destruction of the immune system in humans, caused by HIV. The term AIDS is an acronym derived from the English words, “Acquired Immune Deficiency Syndrome”. HIV (Human Immunodeficiency Virus) diffuses gradually into the immune system destroying the defense of the body against infections and causing the person slowly to become unprotected against various disorders and diseases, finally leading to death.

In state of art technology, invention no "WO 1999/025352" , with title "Combination Therapy for Treatment of AIDS" and under classification number "A61K 31/495" discloses a combination of HIV protease inhibitor compound A with one or more nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors or protease inhibitors, and is useful in HIV protease inhibition, HIV reverse transcriptase inhibition as well as in treatment and prevention of AIDS, in combination with related compounds, pharmaceutically acceptable salts or esters, and with other antivirals, immune-modulators, antibiotics and vaccines as pharmaceutical composition components. Herewith both AIDS treatment methods as well as methods for preventing and treating HIV infection are also explained.

Again invention no " EP1326635B1" , with title "Drug Composition Intended to develop immunity against AIDS” and under classification number " A61K 39/21" discloses drug compositions that can be used to develop immunity against infections related to HIV and a drug composition that consists of at least one HIV antigen and DCchol. Such a composition particularly attracts interest, regarding the IgG and IgA system induction in mucous tissue specific to the administered antigen. The drug composition related to the referred invention can be provided in a particularly advantageous composition, either in liposomal suspension or emulsion form.

Again invention no " EP1373256B1" , with title "Beneficial CCR5 antagonists for medication related to AIDS” and under classification number " C07D 403/06" discloses compounds with formula (I) intended for medication related to HIV disease, rejection of solid organ transplantation, Graft Versus Host disease, inflammatory diseases, atopic dermatosis, asthma, allergies or multiple sclerosis as well as a pharmaceutically acceptable salt or isomer or this compound and at the same time the pharmaceutical compositions and antiviral agents or agents for prevention of inflammation and their compositions are explained. In formula (I) Q, X and Z, are either CH or N; R, R4-R7 and R13, H or alkyl; R1 is H, alkyl, fluoroalkyl, R9-arylalkyl, R9-heteroarylalkyl, alkyl-SO2-, cycloalkyl-SO2-, fluoroalkyl-SO2-, R9-aryl-SO2-, R9-heteroaryl-SO2-, N(R22)(R23)-SO2-, alkyl-C(O)-, cycloalkyl-C(O)-, fluoroalkyl-C(O)-, R9-aryl-C(O)-, NH-alkyl-C(O)- or R9-aryl-NH-C(O)-, R2 is H and R3 is H, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, R9-aryl, R9-arylalkyl, R9-heteroaryl or R9-heteroarylalkyl and when each of X and Z are CH, R3 is alkoxy, R9-aryloxy, R9-heteroaryloxy, alkylC(O)O-, alkylaminoC(O)O-, alkylC(O)NR13-, alkylOC(O)NR13- or alkylaminoC(O)NR13-; or R2 and R3, together are =O, =NOR10, =N-NR11R12 or =CH-alkyl.

Again invention no " EP1765370B1", with title "Parapoxviruses in a combined form with other antiviral agents for treatment of HIV/AIDS” and under classification number "A61K 35/76" discloses methods for using parapoxviruses in a combined form, with other active agents for treatment of viral diseases and particularly HIV infections and AIDS. The referred invention also discloses methods for manufacturing drugs that are based on combination of Parapoxviruses and other antiviral agents. Particularly, the referred invention involves using Parapoxviruses in a combined form with various active agents used for retroviral therapy and Highly Active Antiretroviral Therapy (HAART).

To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation intended for treatment of AIDS.

**Objective of the Invention**

To overcome the disadvantages experienced in state of art technology;

* One objective of the present invention is, for it to display DNA polymerase suppressing capability;
* One other objective of the invention is to enhance endogenous cathelicidin production;
* One other objective of the invention is for it to display reverse transcriptase suppressing capability;
* One other objective of the invention is for it to display ribonucleotide reductase and integrase suppressing capability;
* One other objective of the invention is to enhance endogenous growth hormone secretion and thus to enhance production of t-lymphocytes and b-lymphocytes production;
* One other objective of the invention is for it to have an effect of preventing muscle tissue loss.

The present invention which is aimed to achieve the above-mentioned advantages, is intended for treatment of AIDS and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 3,4,5-pentamethoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-yl](E)-3-(3,4-hydroxyphenyl) prop-2-enoate,  3,4,5-methoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-yl](E)-3-(3,4-methoxyphenyl)prop-4-enoate, 3,5,7-pentamethoxy-6-hydroxyloxane-(3,4-hydroxy phenyl)prop-2-enoate, 7-desmethyl-dioxin-ethyl-ester.

Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith..

**Detailed Description of the Invention**

The present invention is related to a formulation developed for treatment of AIDS. Referred formulation displays DNA polymerase suppressing capability, enhances endogenous cathelicidin production, displays reverse transcriptase suppressing capability, displays ribonucleotide reductase and integrase suppressing capability. It also enhances endogenous growth hormone secretion and thus enhances production of t-lymphocytes and b-lymphocytes and also for the same reason has an effect of preventing muscle tissue loss.

The formulation of the invention presented herewith contains; 3,4,5-pentamethoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-yl](E)-3-(3,4-hydroxyphenyl)prop-2-enoate,  3,4,5-methoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-yl](E)-3-(3,4-methoxyphenyl)prop-4-enoate, 3,5,7-pentamethoxy-6-hydroxyloxane-(3,4-hydroxyphenyl)prop-2-enoate, 7-desmethyl-dioxin-ethyl-ester .

The referred formulation is formed by mixing the above-mentioned components at below percentages by weight;

* 10-22% of 3,4,5-pentamethoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-yl](E)-3-(3,4-hydroxyphenyl)prop-2-enoate,
* 30-18% of 3,4,5-methoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-yl](E)-3-(3,4-methoxyphenyl)prop-4-enoate,
* 20-25% of 3,5,7-pentamethoxy-6-hydroxyloxane-(3,4-hydroxyphenyl)prop-2-enoate,
* 40-35% of 7-desmethyl-dioxin-ethyl-ester.

Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof.

The present invention at the same time is related to using the above-referred formulation for treatment of aids and manufacturing it for such purpose.

**CLAIMS**

1. A formulation intended for treatment of AIDS, which consists of combining the components selected from the group; 3,4,5-pentamethoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-yl](E)-3-(3,4-hydroxyphenyl)prop-2-enoate,  3,4,5-methoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-yl](E)-3-(3,4-methoxyphenyl)prop-4-enoate, 3,5,7-pentamethoxy-6-hydroxyloxane-(3,4-hydroxyphenyl)prop-2-enoate, 7-desmethyl-dioxin-ethyl-ester in a single form or in combinations thereof
2. The formulation of Claim 1, which is characterized by containing 10-22% of 3,4,5-pentamethoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-yl](E)-3-(3,4-hydroxyphenyl)prop-2-enoate by weight.
3. The formulation of Claim 1, which is characterized by containing 30-18% of 3,4,5-methoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-yl](E)-3-(3,4-methoxyphenyl)prop-4-enoate by weight.
4. The formulation of Claim 1, which is characterized by containing 20-25% of 3,5,7-pentamethoxy-6-hydroxyloxane-(3,4-hydroxyphenyl)prop-2-enoate by weight.
5. The formulation of Claim 1, which is characterized by containing 40-35% of 7-desmethyl-dioxin-ethyl-ester by weight.
6. Using the compositions obtained by selecting singly or in combination of components from the group of; 3,4,5-pentamethoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-yl](E)-3-(3,4-hydroxyphenyl)prop-2-enoate,  3,4,5-methoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-yl](E)-3-(3,4-methoxyphenyl)prop-4-enoate, 3,5,7-pentamethoxy-6-hydroxyloxane-(3,4-hydroxyphenyl)prop-2-enoate, 7-desmethyl-dioxin-ethyl-ester from any one as given in Claims 2-5 in manufacturing the formulation intended for treatment of AIDS.

**SUMMARY**

**A FORMULATION INTENDED FOR TREATMENT OF AIDS**

The present invention is related to a formulation developed for treatment of AIDS. Referred formulation displays DNA polymerase suppressing capability, enhances endogenous cathelicidin production, displays reverse transcriptase suppressing capability, displays ribonucleotide reductase and integrase suppressing capability. It also enhances endogenous growth hormone secretion and thus enhances production of t-lymphocytes and b-lymphocytes and also for the same reason has an effect of preventing muscle tissue loss.

There are no illustrations.